Intellectual Property
Osel currently holds eight issued US patents and one Chinese patent (Table I). Four of these patents have broad claims covering medicant and use of vaginal Lactobacillus in female health, and the other four covering use of genetically modified vaginal lactobacilli against viral infections through mucosal membranes (Osel’s MucoCept platform technology).
Table I. A summary of Osel’s issued patents.
| Patent No. | Title | Date of Issue |
|---|---|---|
| 5,733,540 | Protection from Viral Infection Via Colonization of Mucosal Membranes with Genetically Modified Bacteria | 03-31-98 |
| 6,093,394 | Vaginal Lactobacillus Medicament | 07-25-00 |
| 6,365,156 | Method for Improving the Half life of Soluble Viral-Specific Ligands on Mucosal Membranes | 04-02-02 |
| 6,372,209 | Vaginal Lactobacillus Medicament | 04-16-02 |
| 6,468,526 | Vaginal Lactobacillus Medicament | 10-22-02 |
| ZL 98806040.X* | Vaginal Lactobacillus Medicament (*Chinese Patent) | 03-30-05 |
| 7,179,458 | Lactobacilli Expressing Biologically active Peptides and Uses Thereof | 02-20-07 |
| 7,312,076 | Lactobacilli Expressing Biologically active Peptides and Uses Thereof | 12-25-07 |
| 7,456,011 | Modified cyanovirin-N polypeptide | 11-25-08 |
| 7,754,467 | Surface expression of biologically active protein in bacteria | 07-13-10 |
Osel has filed additional patent applications broadly covering Lactobacillus preservation and formulation, and a dosage form for mucosal delivery, and surface display of heterologous proteins on the bacterial cell wall.
These patent applications, along with issued patents and those undergoing prosecution in other regions of the world, will serve to strengthen Osel’s already strong proprietary position surrounding its MucoCept product concepts and technology. Townsend and Townsend and Crew LLP has handled all patent documentation and filings for the company.